Picture of Amgen logo

AMGN — Amgen News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Amgen jolts to record-high after hiking FY forecasts, Q2 results beat

BUZZ-Amgen jolts to record-high after hiking FY forecasts, Q2 results beat 

** Amgen AMGN.O shares jump 6.5% to all-time high of $415.51 in morning trading

** The stock's previous 52-week high was $398

** The Pharma major late Tuesday reported Q2 revenue of $10.1 billion, easily surpassing Wall Street estimates of $9.42 billion

** Q2 adj. EPS - $6.29 per share; analysts on avg expected $5.62, according to data compiled by LSEG

** AMGN also hiked FY forecasts for profit and revenue

** Results driven by strong sales of Repatha, Evenity and rare disease drugs, while Amgen advances its experimental obesity treatment MariTide

** Including session's move, AMGN stock was up 26% YTD


(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Recent news on Amgen

See all news